|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.46/-0.36
|
企业价值
69.28M
|
资产负债 |
每股账面净值
0.27
|
现金流量 |
现金流量率
--
|
损益表 |
收益
675.00K
|
每股收益
0.02
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/25 01:19 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. |